Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection

Table 1 Currently approved¹ direct-acting antivirals combination regimens for hepatitis C virus associated cirrhosis

Drug class	Name	Combination DAA partner	Genotype	Ribavirin	Therapy duration (wk)	Approved cirrhosis class (CPT)
NS3/4A protease inhibitors	Simeprevir	Sofosbuvir	1, 4	No	12	A
	Paritaprevir	In fixed combination with ritonavir and ombitasvir	1, 4	No/Yes	12-24	A
	Grazoprevir	In fixed combination with elbasvir	1, 4	No/Yes	12-16	A
NS5A inhibitors	Daclatasvir	Sofosbuvir	1, 3, 4	No/Yes	12-24	A, B, C
	Ledipasvir	In fixed combination with sofosbuvir	1, 3, 4, 5, 6	No/Yes	12-24	A, B, C2
	Ombitasvir	In fixed combination with paritaprevir and ritonavir	1, 4	No/Yes	12-24	A
	Elbasvir	In fixed combination with grazoprevir	1, 4	No/Yes	12-16	A
	Velpatasvir	In fixed combination with sofosbuvir	1, 2, 3, 4, 5, 6	No/Yes	12	A, B, C
NS5B non-nucleoside analog polymerase inhibitors	Dasabuvir	Ombitasvir/paritaprevir/ritonavir	1	No/Yes	12-24	A
NS5B nucleoside analog polymerase inhibitors	Sofosbuvir	Daclatasvir	1, 2, 3, 4, 5, 63	No/Yes	12-24	A, B, C
		Simeprevir
		Ledipasvir in fixed combination
		Velpatasvir in fixed combination

¹Approved by EMA and/or FDA by October 2016. Approval details may differ with respect to region, genotype, and combination partner;

²Genotype 3, only CPT A;

³Different approvals for SOF/RBV, and SOF/LDV. Adapted from[96]. CPT: Child-Pugh-Turcotte; DAA: Direct-acting antivirals; EMA: European Medicines Agency; FDA: Food and Drug Administration; LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir.